159 related articles for article (PubMed ID: 12968844)
1. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide, and rifampin.
Ahn C; Oh KH; Kim K; Lee KY; Lee JG; Oh MD; Kim Y; Han JS; Kim S; Lee JS; Jang IJ; Shin SG
Perit Dial Int; 2003; 23(4):362-7. PubMed ID: 12968844
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
[TBL] [Abstract][Full Text] [Related]
4. Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis.
Ge Z; Wang Z; Wei M
Eur Spine J; 2008 Nov; 17(11):1482-7. PubMed ID: 18795341
[TBL] [Abstract][Full Text] [Related]
5. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
[TBL] [Abstract][Full Text] [Related]
6. Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
Zuur MA; Pasipanodya JG; van Soolingen D; van der Werf TS; Gumbo T; Alffenaar JC
Clin Infect Dis; 2018 Nov; 67(11):1743-1749. PubMed ID: 29697766
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
[TBL] [Abstract][Full Text] [Related]
11. Serum drug concentrations predictive of pulmonary tuberculosis outcomes.
Pasipanodya JG; McIlleron H; Burger A; Wash PA; Smith P; Gumbo T
J Infect Dis; 2013 Nov; 208(9):1464-73. PubMed ID: 23901086
[TBL] [Abstract][Full Text] [Related]
12. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC
Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
[TBL] [Abstract][Full Text] [Related]
14. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis.
Façanha MC; Gondim AM; Pinheiro VG; Barroso EC; Peloquin CA; Guerrant RL; Lima AA
Braz J Infect Dis; 2009 Jun; 13(3):210-7. PubMed ID: 20191199
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
Peloquin CA; Jaresko GS; Yong CL; Keung AC; Bulpitt AE; Jelliffe RW
Antimicrob Agents Chemother; 1997 Dec; 41(12):2670-9. PubMed ID: 9420037
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
17. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
[TBL] [Abstract][Full Text] [Related]
19. Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis.
Kumar AKH; Kadam A; Karunaianantham R; Tamizhselvan M; Padmapriyadarsini C; Mohan A; Jeyadeepa B; Radhakrishnan A; Singh UB; Bapat S; Mane A; Kumar P; Mamulwar M; Bhavani PK; Haribabu H; Rath N; Guleria R; Khan AM; Menon J;
Ther Drug Monit; 2024 Jun; 46(3):370-375. PubMed ID: 38019456
[TBL] [Abstract][Full Text] [Related]
20. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
